Shopping Cart 0
Cart Subtotal
AED 0

MaxCyte Inc (MXCT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

MaxCyte Inc (MaxCyte) is a biotherapeutic company that conducts research and develops cell transfection technologies. The company offers MaxCyte STX, MaxCyte VLX and MaxCyte GT instruments. It utilizes flow electroporation technology for discovery, development and manufacturing of cell-based therapeutics for chronic and acute diseases. MaxCyte offers services such as transfection in sourcing services, processing assemblies, and others. The company's drug delivery applications comprise GPCR's, Ion channels, primary cell transfusion and maxcyte STX instrument, among others. Its products and services find applications in cell and gene therapy, protein production, cell based assays, gene editing, cell line development, and viral vectors and vaccines. The company markets its products through a network of distributors in the US, Japan, Taiwan and China. MaxCyte is headquartered in Gaithersburg, Maryland, the US.

MaxCyte Inc (MXCT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

MaxCyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

MaxCyte Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

MaxCyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

MaxCyte Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

MaxCyte Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

MaxCyte Inc, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

MaxCyte Raises USD0.8 Million in Venture Financing 10

Partnerships 11

MaxCyte Enters into R&D Agreement with National Heart Lung and Blood Institute 11

Maxcyte Enters into R&D Agreement with National Institute of Allergy and Infectious Diseases 12

MaxCyte Enters into Agreement with Washington University in St Louis 13

MaxCyte Partners with US Army Medical Research Institute Of Infectious Diseases 14

MaxCyte Enters into Research Agreement with Johns Hopkins University 15

Licensing Agreements 16

CRISPR Therapeutics and Casebia Therapeutics Enter into Licensing Agreement with MaxCyte 16

Equity Offering 17

MaxCyte Raises USD25 Million in Private Placement of Shares 17

Asset Transactions 18

Paragon Bioservices Acquires MaxCyte VLX Large Scale Transfection System And MaxCyte STX Scalable Transfection System From MaxCyte 18

MaxCyte Inc-Key Competitors 20

MaxCyte Inc-Key Employees 21

MaxCyte Inc-Locations And Subsidiaries 22

Head Office 22

Other Locations & Subsidiaries 22

Recent Developments 23

Financial Announcements 23

Sep 24, 2018: MaxCyte: Results for the six months ended 30 June 2018 23

Apr 04, 2018: MaxCyte Reports Final Results for Year Ended 31 December 2017 26

Sep 19, 2017: MaxCyte: Results for the Six Months ended 30 June 2017 27

Mar 20, 2017: MaxCyte Reports Final Results for Year Ended 31 December 2016 28

Corporate Communications 29

Feb 13, 2018: MaxCyte Appoints Dr. Richard Douglas To Board 29

Feb 13, 2018: MaxCyte:Dr Richard Douglas Joins MaxCyte Board 30

Aug 14, 2017: MaxCyte Appoints Executive Vice President of Global Marketing 31

Product News 32

Jan 12, 2017: MaxCyte, NIH NIAID Study Published in Science Translational Medicine Demonstrates CRISPR-Cas9 X-Linked CGD Gene Repair 32

Clinical Trials 33

Mar 02, 2017: MaxCyte to Present Pre-Clinical CARMA Data at AACR Meeting 33

Other Significant Developments 34

Jul 12, 2017: MaxCyte: Trading Update 34

Appendix 35

Methodology 35

About GlobalData 35

Contact Us 35

Disclaimer 35


List Of Figure

List of Figures

MaxCyte Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

MaxCyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

MaxCyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

MaxCyte Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

MaxCyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

MaxCyte Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

MaxCyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

MaxCyte Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

MaxCyte Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

MaxCyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

MaxCyte Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

MaxCyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

MaxCyte Inc, Deals By Therapy Area, 2012 to YTD 2018 8

MaxCyte Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

MaxCyte Raises USD0.8 Million in Venture Financing 10

MaxCyte Enters into R&D Agreement with National Heart Lung and Blood Institute 11

Maxcyte Enters into R&D Agreement with National Institute of Allergy and Infectious Diseases 12

MaxCyte Enters into Agreement with Washington University in St Louis 13

MaxCyte Partners with US Army Medical Research Institute Of Infectious Diseases 14

MaxCyte Enters into Research Agreement with Johns Hopkins University 15

CRISPR Therapeutics and Casebia Therapeutics Enter into Licensing Agreement with MaxCyte 16

MaxCyte Raises USD25 Million in Private Placement of Shares 17

Paragon Bioservices Acquires MaxCyte VLX Large Scale Transfection System And MaxCyte STX Scalable Transfection System From MaxCyte 18

MaxCyte Inc, Key Competitors 20

MaxCyte Inc, Key Employees 21

MaxCyte Inc, Other Locations 22

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

MaxCyte Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.